# Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A

Source: https://onco.cc/trials/nct01639508/  
OnCo record `nct01639508` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cabozantinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity is a phase 2, interventional study registered as NCT01639508 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 86 participants, started 2012-07 and due to reach its primary completion in 2027-07. Interventions recorded: Cabozantinib. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: objective response rate (ORR) (Group A); objective response rate (ORR) (Group B). Lung eligibility wording from the registry: "The subject has a pathologic diagnosis of non-small cell lung carcinoma that is metastatic or unresectable". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT01639508
- Phase: 2
- Setting: A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 86

## Sources

- ClinicalTrials.gov NCT01639508: https://clinicaltrials.gov/study/NCT01639508

## Connected records

- cancers: [NTRK fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ntrk-fusion-nsclc/), [RET fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ret-fusion-nsclc/), [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/)
- drugs: [Cabozantinib](https://onco.cc/drugs/cabozantinib/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct01639508.json